for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Fosun Pharmaceutical (Group)

600196.SS

Latest Trade

74.75CNY

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

36.67

 - 

82.74

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
74.75
Open
--
Volume
--
3M AVG Volume
1,344.51
Today's High
--
Today's Low
--
52 Week High
82.74
52 Week Low
36.67
Shares Out (MIL)
2,562.90
Market Cap (MIL)
169,303.10
Forward P/E
39.98
Dividend (Yield %)
0.61

Next Event

Q2 2021 Shanghai Fosun Pharmaceutical Group Co Ltd Earnings Release

Latest Developments

更多

Kintor Pharma Says Unit Entered Proxalutamide Licensing Agreement

JPMorgan Chase & Co's Long Position In Shanghai Fosun Pharma Falls To 4.69% - HKEX Filing

Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Fosun Pharmaceutical (Group)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. It distributes its products primarily in domestic and overseas markets.

Industry

Major Drugs

Contact Info

Building A, No. 1289 Yishan Road

SHANGHAI, SHA

200233

China

+86.21.33987870

http://www.fosunpharma.com

Executive Leadership

Yifang Wu

Chairman of the Board, Chief Executive Officer, Executive Director

Yuqing Chen

Co-President

Dongming Li

Co-President

Kexin Wang

Co-President

Xiaohui Guan

Chief Financial Officer, Executive President

Key Stats

1.92 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

24.9K

2019

28.6K

2020

30.3K

2021(E)

36.6K
EPS (CNY)

2018

1.070

2019

1.300

2020

1.430

2021(E)

1.721
Price To Earnings (TTM)
46.20
Price To Sales (TTM)
5.21
Price To Book (MRQ)
4.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
64.41
LT Debt To Equity (MRQ)
26.26
Return on Investment (TTM)
8.15
Return on Equity (TTM)
5.20

Latest News

Latest News

Fosun-BioNTech COVID-19 vaccine completes China regulator review - media

Chinese regulators have completed an expert review of a COVID-19 mRNA vaccine developed by Germany's BioNTech and Fosun Pharma and the shot is in the administration review stage, Caixin reported, citing the Chinese company.

UPDATE 1-Fosun Pharma to provide factory with annual capacity of 1 bln doses of BioNTech's COVID-19 vaccine

China's Shanghai Fosun Pharmaceutical said its subsidiary has agreed to provide a factory with an annual capacity to make up to 1 billion doses of the COVID-19 vaccine developed by BioNTech .

Fosun Pharma's subsidiary, BioNTech to set up JV for COVID-19 vaccine production

China's Shanghai Fosun Pharmaceutical said on Sunday its subsidiary had agreed to set up a joint venture with BioNTech for the manufacture and commercialisation of the German firm's COVID-19 vaccine.

UPDATE 2-Hong Kong formally approves Fosun Pharma-BioNTech vaccine

Hong Kong has formally approved use of the Fosun Pharma-BioNTech vaccine, the city government said on Monday, the first COVID-19 vaccine to be accepted in the Asian financial hub.

UPDATE 1-China's Fosun plans plant to make BioNTech's COVID-19 vaccine -Caixin

Shanghai Fosun Pharmaceutical Group is planning a facility in China to produce the COVID-19 vaccine developed by Germany's BioNTech , financial magazine Caixin reported on Wednesday.

China's Fosun to set up JV with BioNTech to make COVID-19 vaccines-Caixin

Shanghai Fosun Pharmaceutical Group will set up a joint venture with Germany's BioNTech to produce COVID-19 vaccines in China, financial magazine Caixin reported on Wednesday.

China approves Shanghai Fosun's unit to run human testing for BioNTech's COVID-19 vaccine

Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China's National Medical Products Administration for a COVID-19 vaccine candidate developed by German firm BioNTech.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up